{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:45:48Z","timestamp":1789908348626,"version":"4.0.1"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T00:00:00Z","timestamp":1444003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec><jats:label\/><jats:p>Minority variants (1.0\u201325.0%) were evaluated by deep sequencing (DS) at baseline and virological failure (VF) in a selection of antiretroviral treatment\u2010na\u00efve, HIV\u20101\u2010infected patients from the rilpivirine ECHO\/THRIVE phase III studies. Linkage between frequently emerging resistance\u2010associated mutations (RAMs) was determined. DS (llIumina\u00ae) and population sequencing (PS) results were available at baseline for 47 VFs and time of failure for 48 VFs; and at baseline for 49 responders matched for baseline characteristics. Minority mutations were accurately detected at frequencies down to 1.2% of the HIV\u20101 quasispecies. No baseline minority rilpivirine RAMs were detected in VFs; one responder carried 1.9% F227C. Baseline minority mutations associated with resistance to other non\u2010nucleoside reverse transcriptase inhibitors (NNRTIs) were detected in 8\/47 VFs (17.0%) and 7\/49 responders (14.3%). Baseline minority nucleoside\/nucleotide reverse transcriptase inhibitor (NRTI) RAMs M184V and L210W were each detected in one VF (none in responders). At failure, two patients without NNRTI RAMs by PS carried minority rilpivirine RAMs K101E and\/or E138K; and five additional patients carried other minority NNRTI RAMs V90I, V106I, V179I, V189I, and Y188H. Overall at failure, minority NNRTI RAMs and NRTI RAMs were found in 29\/48 (60.4%) and 16\/48 VFs (33.3%), respectively. Linkage analysis showed that E138K and K101E were usually not observed on the same viral genome. In conclusion, baseline minority rilpivirine RAMs and other NNRTI\/NRTI RAMs were uncommon in the rilpivirine arm of the ECHO and THRIVE studies. DS at failure showed emerging NNRTI resistant minority variants in seven rilpivirine VFs who had no detectable NNRTI RAMs by PS. <jats:bold><jats:italic>J. Med. Virol. 88:798\u2013806, 2016<\/jats:italic>.<\/jats:bold> \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.24395","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T09:42:47Z","timestamp":1443433367000},"page":"798-806","source":"Crossref","is-referenced-by-count":12,"title":["Deep sequencing analysis of HIV\u20101 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE"],"prefix":"10.1002","volume":"88","author":[{"given":"Veerle","family":"Van Eygen","sequence":"first","affiliation":[{"name":"Janssen Infectious Diseases BVBA Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Thys","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases BVBA Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Van Hove","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence T.","family":"Rimsky","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases BVBA Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"De Meyer","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases BVBA Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Aerssens","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases BVBA Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Picchio","sequence":"additional","affiliation":[{"name":"Janssen Research and Development Titusville New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vingerhoets","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases BVBA Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019461"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60983-5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824d006e"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835cee6e"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2011.04.023"},{"key":"e_1_2_9_7_1","unstructured":"European AIDS Clinical Society.2014. EACS European Guidelines for treatment of HIV infected adults in Europe. Version 7.1. Available at:http:\/\/www.eacsociety.org\/Portals\/0\/140601_EACS%20EN7.02.pdf. Accessed February 11 2015."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02582-10"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283427dcb"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/v6093428"},{"key":"e_1_2_9_11_1","unstructured":"HaddadM NapolitanoLA PaquetA EvansM PetropoulosC WhitcombJ HuangW.2012. Mutation Y188L of HIV\u20101 reverse transcriptase is strongly associated with reduced susceptibility to rilpivirine. 19th Conference on Retroviruses and Opportunistic Infections. Seattle WA. Abstract 695."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110064108"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182515730"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.375"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834e9d7d"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000222071.60620.1d"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050158"},{"key":"e_1_2_9_18_1","first-page":"156","article-title":"2011 Update of the drug resistance mutations in HIV\u20101","volume":"19","author":"Johnson VA","year":"2011","journal-title":"Top Antivir Med"},{"key":"e_1_2_9_19_1","unstructured":"MackieN GarveyL GerettiAM HarrisonL TilstonP PhillipsA SabinC DunnD.2011. Predicting NNRTI resistance: Do polymorphisms matter? 18th Conference on Retroviruses and Opportunistic Infections. Boston MA USA. Abstract 595."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2012.01.002"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2010.10.001"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60936-7"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr344"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2007.06.012"},{"key":"e_1_2_9_25_1","first-page":"662","article-title":"Pre\u2010existing minority drug\u2010resistant HIV\u20101 variants, adherence, and risk of antiretroviral treatment failure","volume":"201","author":"Paredes R","year":"2010","journal-title":"J Infect Dis"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31823df4da"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2009.0082"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.7.2291-2296.1999"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/596736"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.398180"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2015.04.022"},{"key":"e_1_2_9_32_1","unstructured":"US Department of Health and Human Services.2014. DHHS Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents. Available at:http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed February 11 2015."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2358"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.24395","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.24395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T13:49:34Z","timestamp":1696600174000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.24395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/jmv.24395"],"URL":"https:\/\/doi.org\/10.1002\/jmv.24395","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,5]]}}}